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Abstract
Objective—To determine the association of PaCO2 with severe intraventricular hemorrhage 
(sIVH), bronchopulmonary dysplasia (BPD), and neurodevelopmental impairment (NDI) at 18–22 
months in premature infants.
Design—Secondary exploratory data analysis of SUPPORT.
Setting—Multiple referral NICUs.
Patients—1316 infants 24 0/7 to 27 6/7 weeks gestation randomized to different oxygenation 
(SpO2 target 85–89% vs 91–95%) and ventilation strategies.
Main Outcome Measures—Blood gases from postnatal days 0–14 were analyzed. Five PaCO2 
variables were defined: minimum [Min], maximum [Max], standard deviation, average (time-
weighted), and a 4 level categorical variable (hypercapnic [highest quartile of Max PaCO2], 
hypocapnic [lowest quartile of Min PaCO2], fluctuators [both hypercapnia and hypocapnia], and 
normocapnic [middle two quartiles of Max and Min PaCO2]). PaCO2 variables were compared for 
infants with and without sIVH, BPD, and NDI (+/− death). Multivariable logistic regression 
models were developed for adjusted results.
Results—sIVH, BPD, and NDI (+/− death) were associated with hypercapnic infants and 
fluctuators. Association of Max PaCO2 and outcomes persisted after adjustment (Per 10 mmHg 
increase: sIVH/death: OR 1.27 [1.13–1.41]; BPD/death: OR 1.27 [1.12–1.44]; NDI/death: OR 
1.23 [1.10–1.38], Death: OR 1.27 [1.12–1.44], all p <0.001). No interaction was found between 
PaCO2 category and SpO2 treatment group for sIVH/death, NDI/death, or death. Max PaCO2 was 
positively correlated with maximum FiO2 (rs0.55, p<0.0001) & ventilator days (rs0.61, p<0.0001).
Conclusions—Higher PaCO2 was an independent predictor of sIVH/death, BPD/death, and 
NDI/death. Further trials are needed to evaluate optimal PaCO2 targets for high risk infants.
Keywords
Infant; premature; Infant mortality; Infant; Premature; Diseases/epidemiology; Predictive value of 
tests; Prognosis; Intracranial hemorrhage; Blood Gas Analysis
INTRODUCTION
Variations in arterial partial pressure of carbon dioxide (PaCO2) are associated with 
outcomes of prematurity such as intraventricular hemorrhage (IVH),1 periventricular 
leukomalacia (PVL),2, 3 bronchopulmonary dysplasia (BPD),4 and neurodevelopmental 
impairment (NDI).5 We have previously shown that both high and low PaCO2 and wide 
fluctuations in PaCO2 are associated with severe IVH (sIVH; IVH Grades III or IV).1 
Periventricular leukomalacia (PVL) is associated with hypocapnia.2, 3, 6
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Increased PaCO2 increases cerebral blood flow,7–9 while decreased PaCO2 reduces cerebral 
blood flow.10 Cerebral blood flow decreases with increased oxygenation9 but interactions 
between PaCO2 and oxygenation have not been assessed in preterm infants. Lung injury 
may be reduced by tolerance of higher PaCO24, 11, 12 as well as lower oxygen saturation 
(SpO2).13 The combination of higher PaCO2 (permissive hypercapnia) and lower SpO2 
might reduce BPD more than with either permissive hypercapnia or a lower SpO2 target 
alone.
The NICHD Neonatal Research Network SUPPORT trial compared outcomes in infants 
randomly assigned to SpO2 targets of either 85–89% or 91–95%, while also randomly 
allocated to either early CPAP and a limited ventilation strategy (PaCO2>65 mm Hg 
permitted intubation, while PaCO2<65 mm Hg with pH>7.20 was an extubation criterion) or 
intubation and surfactant (PaCO2<50 mm Hg with pH>7.30 was an extubation 
criterion).13, 14 Death and other major outcomes did not differ significantly by CPAP vs. 
intubation/surfactant groups although CPAP group infants received fewer days of 
mechanical ventilation.13, 14 In the lower SpO2 target group, death occurred more frequently 
(19.9 vs. 16.2%; p= 0.04) while severe retinopathy among survivors occurred less often (8.6 
vs. 17.9%; p<0.001), without significant differences in other outcomes.13 However, no 
significant differences in the composite outcome of death or NDI were noted among infants 
in any of the treatment groups.15
Clinical outcomes not significantly different by SpO2 target groups might be different when 
the combination of PaCO2 and SpO2 (actual or target group) is analyzed. We hypothesized 
that both extremes of PaCO2 would be associated with sIVH, and that effect modification by 
SpO2 would be observed, with hypercapnia associated with sIVH in the low but not high 
SpO2 group (due to greater cerebral blood flow at lower SpO2). We also hypothesized that 
BPD would be lower in infants with hypercapnia in the low SpO2 group (due to less 
mechanical ventilation), and that higher PaCO2 will be associated with a higher NDI (due to 
increased risk of sIVH).
PATIENTS AND METHODS
Patient characteristics
This was a secondary exploratory analysis of data from infants (n=1316) in the SUPPORT 
trial.13, 14 Characteristics of this population13 (mean birth weight approximately 830 g, 
gestational age 26 weeks, 54% male) and the follow-up cohort15 (93.6% evaluated at 18–22 
months corrected age, 20.1% death, 28.8% with NDI/death) have been previously reported.
PaCO2 variables
Five PaCO2 variables were defined, using routine blood gas (arterial or capillary) 
measurements not governed by protocol. PaCO2 closest to 8 am, 4 pm, and midnight was 
recorded for postnatal days 1–14. From these data, the minimum, maximum (Max PaCO2), 
standard deviation, and average (time-weighted) PaCO2 were derived. Average (time-
weighted) PaCO2 was calculated as defined previously1: the sum of all PaCO2 values 
multiplied by the time interval from previous blood gas was divided by the overall time 
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period. This measure enables an estimate of the magnitude of exposure to PaCO2 by taking 
into account the duration of time for each PaCO2 value. To avoid any one blood gas value 
from having an unduly large effect in this “time-weighting”, we capped the maximum 
duration for any PaCO2 at 24h. Infants were categorized into 4 groups (hypercapnic, 
hypocapnic, fluctuators, and normocapnic) by first separately ranking the maximum and 
minimum PaCO2 over days 1–14 into quartiles. Infants with minimum PaCO2 in lowest 
quartile and not in highest quartile of maximum PaCO2 were categorized as ‘hypocapnic’. 
Infants with maximum PaCO2 in highest quartile and not in lowest quartile of minimum 
PaCO2 were considered ‘hypercapnic’. Infants in both lowest quartile of minimum PaCO2 
and highest quartile of maximum PaCO2 were considered ‘fluctuators’. Remaining infants 
with minimum PaCO2 level in quartiles 2–4 and maximum PaCO2 in quartiles 1–3 were 
categorized as ‘normocapnic’.
Other variables
Maternal hypertension was defined as pregnancy-induced hypertension (PIH). Premature 
rupture of membranes (PROM) was rupture of membranes > 24 hours prior to birth. Prenatal 
steroids were any use of antenatal steroids. Maximum FiO2 was the maximum FiO2 at 24 
hours and on days 3, 7, and 14. Severe illness was defined a priori as FiO2 >0.4 and 
mechanical ventilation for 8+ hours in the 1st 14 days. sIVH was IVH grade 3–4.16 BPD was 
defined using the physiologic definition at 36w PMA.17, 18 NDI was any of: a cognitive 
composite score on the Bayley Scales of Infant and Toddler Development, third edition < 
70, a modified Gross Motor Function Classification System score ≥2, moderate or severe 
cerebral palsy, hearing impairment, or bilateral visual impairment.15 PVL was not evaluated 
as the incidence (4%) was too low for detailed analysis.
Statistical Analysis
PaCO2 and other variables for infants with outcome were compared to those without 
outcome for each of 7 outcomes: sIVH, sIVH or death, BPD, BPD or death, NDI, and NDI 
or death, and death by discharge. PaCO2 variables were also compared by SpO2 treatment 
groups. Statistical significance (p<0.05) for these unadjusted comparisons was assessed by 
Chi Square tests for categorical variables and the Wilcoxon-Mann-Whitney test for 
continuous variables. In keeping with the exploratory goals of this study, no adjustments 
were made for multiple comparisons.
Adjusted results for maximum PaCO2, 4 level PaCO2 variable, as well as average PaCO2 
were obtained using generalized estimating equations, assuming an exchangeable correlation 
between infants within familial clusters (i.e. multiples). Other variables included were birth 
weight, GA group (24–25 vs. 26–27 weeks), gender, race, prenatal steroids, PIH, PROM, 
center, and three measures of illness severity: maximum FiO2, severe illness, number of 
mechanical ventilation days in first 14 days. SUPPORT treatment group variables 
(High/Low SpO2; CPAP/ventilator) were included in models containing maximum PaCO2 
and the 4 level PaCO2 variable. Interactions of PaCO2 and treatment group variables 
assessed if effect of PaCO2 varied by SUPPORT treatment group. Evaluation of interaction 
of actual median SpO2 in the first 14 days and average PaCO2 determined if the effect of 
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average PaCO2 varied by level of actual SpO2. Results are expressed as adjusted odds ratios 
and 95% confidence intervals.
As higher maximum PaCO2 may be either deliberate (clinician intent for permissive 
hypercapnia, possibly accompanied by fewer days of mechanical ventilation for comparable 
illness severity) or due to more severe pulmonary disease (associated with higher maximum 
FiO2, days of mechanical ventilation, and severe illness), correlations of maximum PaCO2 
with maximum FiO2 and days of ventilation, and its relationship with severe illness (as 
previously defined) were calculated.
All analyses were done using SAS software v. 9.3 (SAS Institute Inc., Cary, NC).
RESULTS
Adjusted results for sIVH /Death (Table 1):
Higher maximum PaCO2 was associated with increased odds of sIVH/death. Hypercapnic 
infants had higher odds of sIVH/death compared to normocapnic infants whereas 
hypocapnic and fluctuators did not differ significantly. No interaction was found between 
PaCO2 category (Hypocapnic, Hypercapnic, etc) and treatment group (Higher or Lower 
SpO2). Average PaCO2 was not associated with the outcome. Other variables associated 
with sIVH/death included severe illness, lower birth weight and gestational age, male 
gender, no PIH, and center.
Adjusted results for BPD/Death (Table 2):
Higher maximum and average PaCO2 were associated with BPD/death. Interaction 
(p=0.026) was noted between the PaCO2 category ‘fluctuators’ and treatment group (Higher 
or Lower SpO2), hence results for PaCO2 category are presented separately. For fluctuators 
in the higher SpO2 group, the OR was 3.3 vs. 0.62 for fluctuators in the lower SpO2 group. 
Other variables associated with BPD/death were severe illness, lower birth weight, male 
gender, not being non-Hispanic white, and center. As growth restriction increases the risk of 
BPD/death,19 birth weight z-score was initially included in the model, but did not change 
odds ratios, and was therefore excluded from the final model.
Adjusted results for NDI/Death (Table 3):
Higher maximum PaCO2 was associated with NDI/death. No interactions were noted 
between PaCO2 category and SpO2 treatment group. Hypercapnic infants and fluctuators, 
but not hypocapnic infants, had increased odds of NDI/death. Other variables associated 
with NDI/death were severe illness, lower birth weight and gestational age, male gender, 
and no PIH.
Adjusted results for Death before discharge (Table 4):
Higher maximum PaCO2 was associated with death before discharge. No interactions were 
noted between PaCO2 category and SpO2 treatment group. Hypercapnic infants, but not 
hypocapnic and fluctuators, had increased odds of death, versus normocapnic infants. Other 
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variables associated with death were severe illness, lower birth weight, male gender, and no 
PIH.
Maximum PaCO2 was positively correlated with both maximum FiO2 (Spearman correlation 
coefficient [rs] = 0.55, p<0.0001) and days of ventilation (rs = 0.61, p<0.0001). PaCO2 in 
infants having severe illness was higher than in infants without severe illness (median 
maximum PaCO2=78 vs. 61, p <0.0001).
Unadjusted Results (Supplemental Table):
Infants developing sIVH had a lower minimum, higher maximum and greater variation in 
PaCO2 compared to those without sIVH. Maximum PaCO2 demonstrated the largest 
magnitude of separation, with a difference of almost 10 mm Hg in the mean and median 
maximum PaCO2. Separation in minimum, standard deviation, and average PaCO2 was 
statistically significant (p<0.01) but clinically small (~2 mm Hg). Results for BPD, BPD or 
death, NDI, and NDI or death were similar to results for sIVH and sIVH or death. There 
were no significant differences in the PaCO2 variables by SpO2 treatment groups.
DISCUSSION
We found that a higher maximum PaCO2 in the first two postnatal weeks was an 
independent predictor of worse outcome even after adjustment for available indicators of 
illness severity such as maximum FiO2, days of ventilation, and severe illness. However, it 
is not certain that high PaCO2 is in the causal pathway of these outcomes. As statistical 
adjustment in the analysis can only adjust for known variables and not unknown or 
unmeasured variables (e.g. oxygenation index), and PaCO2 was correlated with duration of 
ventilation and oxygen requirement, generally considered markers of illness severity, it is 
possible that high PaCO2 is a surrogate marker for some of these unknown/unmeasured 
variables. Our results suggest that further trials are needed to evaluate optimal PaCO2 targets 
in extremely premature infants.
A limitation is that data on ventilator settings and oxygenation index were not available to 
better estimate lung disease severity. However, this study has the strengths of prospective 
data collection by trained research coordinators and follow-up in almost 94% of infants by 
certified personnel in SUPPORT, a large recent multi-center trial.15 An additional strength is 
that we evaluated both interaction with actual saturation and treatment group (higher or 
lower SpO2 target), to distinguish illness severity and effects of treatment group allocation 
(e.g. higher average PaCO2 was associated with sIVH/death only if actual SpO2 was lower, 
but without interaction with treatment group (see Table 1)).
In this cohort, the average PaCO2 even in infants without sIVH was ≥48 mm Hg with a 
relatively narrow interquartile range (~10 mm Hg). Our data suggest clinical practices have 
evolved to maintain PaCO2 in the “permissive hypercapnia” range (45–55 mm Hg).12 
However, tight control of PaCO2 within this narrow range is difficult as the maximum 
PaCO2 exceeded this range even in infants without sIVH.
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Hypercapnic infants had higher odds of sIVH/death and death even after statistical 
adjustment for illness severity, indicating that higher maximum PaCO2 is an independent 
risk factor for these adverse outcomes. Maximum PaCO2 correlated with longer mechanical 
ventilation and higher oxygen supplementation, suggesting that infants with higher 
maximum PaCO2 had more severe lung disease, rather than permissive hypercapnia and 
more aggressive weaning from mechanical ventilation. No interaction was observed between 
maximum PaCO2 and SpO2 groups for sIVH, probably because randomization in this trial 
likely led to a similar range of lung disease severity and resultant PaCO2 in both SpO2 
groups.
A higher maximum, average, and greater fluctuation in PaCO2 were associated with a 
greater risk of BPD and BPD/death (see Table 2). This may be due to more severe lung 
disease being associated with a higher PaCO2 (even after statistical adjustment for 
maximum FiO2, days of ventilation, and severe illness) rather than because of physician 
intent (similar to sIVH/death). Although hypercapnia was associated with increased illness 
severity and worse outcomes, hypercapnia within a limited range may be acceptable and 
beneficial. Hypercapnia increases CO2 elimination for a given minute ventilation, due to a 
higher alveolar CO2. Also, hypercapnia stimulates respiratory drive, assisting in ventilator 
weaning. An interesting unexplained finding was that greater fluctuation in PaCO2 was 
associated with BPD/death only in the higher SpO2 but not in the low SpO2 group. It is 
speculated that greater oxygen exposure in the higher SpO2 group may interact with 
volutrauma/atelectrauma associated with fluctuating PaCO2 possibly increasing the risk for 
BPD/death.
Maximum PaCO2 was associated with higher NDI/death (see Table 3). This association may 
be secondary to maximum PaCO2 being an indicator of illness severity, but it is also known 
that alterations in PaCO2 can directly mediate brain injury. Increased cerebral blood flow 
secondary to a spike in PaCO27–9 may result in sIVH1 while reduced flow due to decreased 
PaCO210 may result in PVL.2, 3, 6
In conclusion, our work demonstrates that higher and greater fluctuations of PaCO2 are 
independent predictors of worse outcome in ELBW infants. Higher PaCO2 levels are also 
correlated with a greater magnitude of lung disease. Therefore, similar to oxygenation index, 
maximum PaCO2 or magnitude of fluctuation of PaCO2 may be useful for risk-stratification 
in clinical trials or for prognosis. However, physician intent cannot be entirely ruled out, and 
caution may be needed about intentional use of high PaCO2 soon after birth in ELBW 
infants, until optimal targets of PaCO2 range are established in randomized clinical trials.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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BSID Bayley Scales of Infant Development
CP Cerebral palsy
IVH Intraventricular hemorrhage
sIVH severe intraventricular hemorrhage
NICU neonatal intensive care unit
NDI Neurodevelopmental impairment
PIH Pregnancy Induced Hypertension
PVL Periventricular leukomalacia
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What’s known on this topic
• Variations in arterial partial pressure of carbon dioxide (PaCO2) are associated 
with adverse outcomes of prematurity such as intraventricular hemorrhage, 
periventricular leukomalacia, bronchopulmonary dysplasia, and subsequent 
neurodevelopmental impairment.
What this study adds
• Higher PaCO2 was associated with death or severe intraventricular hemorrhage, 
bronchopulmonary dysplasia, and neurodevelopmental impairment.
• Maximum PaCO2 is a marker of respiratory illness severity in extremely 
premature infants.
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Table 1
Adjusted results for PaCO2 variables in relation to outcome of sIVH /death
PaCO2 Variable Adjusted Odds Ratio (95% CI) p-value
Max PaCO2 (per 10 mm Hg) 1.27 (1.13–1.41) <0.0001
PaCO2 Category:
Hypocapnic 1.16 (0.76–1.78) 0.50
Hypercapnic 1.62 (1.05–2.51) 0.029
Fluctuator 1.68 (0.95–2.97) 0.077
Normocapnic REFERENCE -
Average PaCO2 (per 10 mm Hg) 1.11 (0.80–1.55) 0.52
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Table 2
Adjusted results for PaCO2 variables in relation to outcome of BPD/death
PaCO2 Variable Adjusted Odds Ratio (95% CI) p-value
Max PaCO2 (per 10 mm Hg) 1.27 (1.12–1.44) 0.0002
PaCO2 Category: Higher SpO2 Target
Hypocapnic 0.78 (0.48–1.3) 0.34
Hypercapnic 1.24 (0.67–2.29) 0.49
Fluctuator 3.28 (1.1–9.79) 0.03
Normocapnic REFERENCE -
Lower SpO2 Target
Hypocapnic 1.07 (0.64–1.79) 0.79
Hypercapnic 1.71 (0.95–3.07) 0.07
Fluctuator 0.62 (0.23–1.69) 0.35
Normocapnic REFERENCE -
Average PaCO2 (per 10 mm Hg) 1.65(1.24–2.21) 0.0007
**
interaction term for PaCO2 category × treatment group (Higher or Lower SpO2) was significant for Fluctuators
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Table 3
Adjusted results for PaCO2 variables in relation to outcome of NDI/death
PaCO2 Variable Adjusted Odds Ratio (95% CI) p-value
Max PaCO2 (per 10 mm Hg) 1.23 (1.10–1.38) 0.0003
PaCO2 Category:
Hypocapnic 1.11 (0.73–1.68) 0.63
Hypercapnic 1.75 (1.15–2.65) 0.009
Fluctuator 2.04 (1.16–3.6) 0.014
Normocapnic REFERENCE -
Average PaCO2 (per 10 mm Hg) 1.11 (0.79–1.56) 0.55
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Table 4
Adjusted results for PaCO2 variables in relation to outcome of death before discharge
PaCO2 Variable Adjusted Odds Ratio (95% CI) p-value
Max PaCO2 (per 10 mm Hg) 1.27 (1.12–1.44) 0.0002
PaCO2 Category:
Hypocapnic 0.96 (0.56–1.63) 0. 86
Hypercapnic 1.65 (1.02–2.66) 0.04
Fluctuator 1.17 (0.60–2.31) 0.64
Normocapnic REFERENCE -
Average PaCO2 (per 10 mm Hg) 1.26 (0.88–1.82) 0.20
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